PEG4-aminooxy-MMAF

PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4[1].

Product Specifications

CAS Number

[1415246-35-3]

Product Name Alternative

Amberstatin; AS269

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Drug-Linker Conjugates for ADC; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/peg4-linker.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC([C@H](CC1=CC=CC=C1)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCOCCOCCOCCON)=O)=O)=O)OC)=O)=O

Molecular Formula

C47H82N6O12

Molecular Weight

923.19

Precautions

H302, H315, H319, H335

References & Citations

[1]Mukherjee A, et al. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers (Basel) . 2024 Oct 17;16 (20) :3517.